What Drives This Animal Health Business?
Zoetis develops and sells medicines, vaccines, diagnostics, and related products for animal health. Its portfolio spans both livestock and companion animals, serving veterinarians, livestock producers, and pet owners through animal-health channels. The business sits within pharmaceuticals, with a model built around recurring demand for animal care products. Zoetis operates at large scale, with a market value around USD 50.9 billion.
Are Profit Margins Holding Up Amid Slow Growth?
FundamentalsFor 2025, reported in USD, revenue was USD 9.47 billion and net income was USD 2.67 billion. Cash ended the year at USD 2.31 billion alongside reported total debt of USD 0, while profitability remained high on a trailing basis, with a 71.89% gross margin and a 35.49% operating margin.
Capital spending was USD 621 million in 2025, exceeding depreciation and amortization of USD 487 million. Revenue grew 2.3% versus the prior year, and the trailing net profit margin was 28.23%.
Is The Market Pricing Stability Fairly?
DCF / MultiplesAt USD 112.54, the share price sits slightly below a DCF range that runs from USD 73.74 in a weaker outcome to USD 118.66 centrally and USD 169.86 in a stronger outcome. Headline pricing also lines up with a 17.58 P/E (TTM) and 14.67 EV/EBITDA (TTM).
Durability Matters More Than Growth
TakeawayThe balance sheet looks clean, with no reported debt. That puts the focus on keeping margins and cash conversion steady. Capex running above depreciation raises the bar for sustained cash generation. If growth stays low, valuation support leans heavily on durability. Any margin slip would matter more without faster revenue growth.